US-based drug company Eli Lilly will finance a phase 1 study in the US for Laekna's (HKG:2105) LAE102 anti-obesity drug, according to a Wednesday filing with the Hong Kong Exchange.
The drug helps target the ActRIIA receptor that helps with muscle regeneration and lipid metabolism, the filing said.
Preclinical trials showed the drug helps boost muscular mass and decreases fat, the filing said.